GRAFAPEX (treosulfan) for Injection Receives CMS Approval of New Technology Add-On Payment (NTAP) for Eligible Cases in CMS's Fiscal Year 2026

Stock Information for Medexus Pharmaceuticals Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Medexus Pharmaceuticals Inc.

Medexus Announces Normal Course Issuer Bid, or NCIB, for Its Common Shares
Medexus Announces US$51.0 million in New Credit Facilities and Intention to Commence Normal Course Issuer Bid, or NCIB, for its Common Shares
Medexus Announces Fiscal Q2 2026 Results, Driven by Strong Year-To-Date Product-Level Performance of GRAFAPEX (treosulfan) for Injection
Medexus Schedules Second Fiscal Quarter 2026 Conference Call
Medexus Holds Annual Meeting of Shareholders and Announces Election of Directors
Medexus Announces Fiscal Q1 2026 Results, Including Positive Results from US Launch of GRAFAPEX (treosulfan) for Injection
Medexus Schedules First Fiscal Quarter 2026 Conference Call
Medexus Announces Strong Fiscal Year 2025 Results, Including Initial Results from Launch of GRAFAPEX (treosulfan) for Injection in the United States

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.